liposomal annamycin
Small moleculeexperimental
Clinical trial activity
9 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
8
Phase 2
7
Phase 3
1
Phase 4
0
Earliest trial started Sep 1, 1998 (NCT00012129)
Timeline
Indications
Mechanism of action
- Unspecified targetUnclear
unclear
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- liposomal annamycin
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06788756 | Phase 2/Phase 3 (Phase 3) | Mar 12, 2025 | Moleculin, LLC |
| NCT05319587 | Phase 1/Phase 2 (Phase 2) | Sep 29, 2022 | Moleculin, LLC |
| NCT05518526 | Phase 1/Phase 2 (Phase 2) | Aug 23, 2022 | Curie Institute |
| NCT04887298 | Phase 1/Phase 2 (Phase 2) | Jun 5, 2021 | Moleculin, LLC |
| NCT03388749 | Phase 1/Phase 2 (Phase 2) | Aug 31, 2018 | Moleculin, LLC |
| NCT03315039 | Phase 1/Phase 2 (Phase 2) | Mar 28, 2018 | Moleculin, LLC |
| NCT00430443 | Phase 1 | Feb 1, 2007 | Callisto Pharmaceuticals |
| NCT00271063 | Phase 1/Phase 2 (Phase 2) | Oct 1, 2005 | Callisto Pharmaceuticals |
| NCT00012129 | Phase 1/Phase 2 (Phase 2) | Sep 1, 1998 | National Cancer Institute (NCI), New York University |
Showing 9 of 9 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Moleculin, LLC | For profit | 5 | 5 | 2 | 2018 |
| Callisto Pharmaceuticals | For profit | 2 | 2 | 2 | 2005 |
| Curie Institute | Academic/Hospital | 1 | 1 | 1 | 2022 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 1998 |
| New York University | Academic/Hospital | 1 | 1 | 1 | 1998 |
5 organizations
Page 1 / 1